A Study of ASP1570 Alone or in Combination with Pembrolizumab or Standard Therapies in Adults with Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Astellas Pharma Global Development Inc.
- Target Recruit Count
- 98
- Registration Number
- 2023-505084-37-00
- Locations
- 🇪🇸
Institut Catala D'oncologia, L'hospitalet De Llobregat, Spain
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
🇪🇸Complexo Hospitalario Universitario De Santiago, Santiago De Compostela, Spain
A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder
- Conditions
- Opioid Use Disorder
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT05062577
A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 453
- Registration Number
- NCT05033886
- Locations
- 🇧🇪
Site BE32005, Tienen, Vlaams Brabant, Belgium
🇨🇦Site CA15008, Brampton, Ontario, Canada
🇨🇦Site CA15010, London, Ontario, Canada
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
- Conditions
- Urinary Bladder NeoplasmsNMIBCCarcinoma Transitional CellNon-muscle Invasive Bladder CancerCarcinoma in Situ
- Interventions
- Drug: Enfortumab vedotin
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT05014139
- Locations
- 🇺🇸
Stanford Health Care, Stanford, California, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04942964
- Locations
- 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Inc, Orlando, Florida, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04939701
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
- Conditions
- Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04855201
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
- Conditions
- Advanced MalignanciesAdvanced Cancer
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04837196
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸University of Iowa Hospitals, Iowa City, Iowa, United States
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
- Conditions
- Prostate CancerMetastatic Castration Resistant Prostate CancerMetastatic Castration-sensitive Prostate Cancer
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04729114
- Locations
- 🇺🇸
Los Angeles Cancer Network, Anaheim, California, United States
🇺🇸Arizona Urology Specialists, Tucson, Arizona, United States
🇺🇸Providence Medical Group Oncology Santa Rosa, Santa Rosa, California, United States
A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function
- Conditions
- Pharmacokinetics of ASP2215Normal Renal FunctionRenal ImpairedGilteritinib
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04699877
- Locations
- 🇺🇸
National Institute of Clinical Research, Garden Grove, California, United States
🇺🇸Orange County Research Institute, Tustin, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States